What is the recommended dose of Crestor (rosuvastatin) for patients post-acute coronary syndrome (ACS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 1, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Rosuvastatin Dose Post-Acute Coronary Syndrome

For patients post-acute coronary syndrome (ACS), high-intensity rosuvastatin at a dose of 20-40 mg daily is recommended to achieve the target LDL-C reduction of at least 50% from baseline and/or achieve an LDL-C level <1.4 mmol/L (<55 mg/dL). 1

Dosing Recommendations

Primary Recommendation

  • Rosuvastatin 20-40 mg daily is the recommended dose post-ACS 1, 2
  • Rosuvastatin 40 mg provides the greatest LDL-C reduction (approximately 46.8%) 3
  • Rosuvastatin 20 mg provides similar LDL-C reduction to atorvastatin 80 mg 3

Treatment Goals

  1. Reduce LDL-C by at least 50% from baseline 1, 2
  2. Achieve LDL-C level <1.4 mmol/L (<55 mg/dL) 1, 2
  3. For patients with recurrent vascular events within 2 years despite maximum statin therapy, consider an even lower LDL-C goal of <1.0 mmol/L (<40 mg/dL) 2

Evidence Supporting High-Intensity Statin Therapy

The 2021 European Society of Cardiology (ESC) guidelines for non-ST-segment elevation acute coronary syndromes specifically recommend high-intensity statin therapy for all ACS patients 1. The guidelines define high-intensity statin therapy as rosuvastatin ≥20 mg or atorvastatin ≥40 mg daily 1, 2.

This recommendation is supported by:

  • Main quality indicator from ESC guidelines: "proportion of patients discharged from hospital on high-intensity statins (defined as atorvastatin ≥40 mg or rosuvastatin ≥20 mg)" 1
  • Clear statement that "statins are recommended in all NSTE-ACS patients" with the aim to reduce LDL-C by at least 50% from baseline and/or achieve LDL-C <1.4 mmol/L (<55 mg/dL) 1

Comparative Efficacy

The LUNAR study demonstrated that:

  • Rosuvastatin 40 mg was significantly more effective than atorvastatin 80 mg in lowering LDL-C (46.8% vs. 42.7% decrease, p=0.02) 3
  • Rosuvastatin 40 mg produced greater increases in HDL-C (11.9%) compared to atorvastatin 80 mg (5.6%) 3
  • Rosuvastatin 20 mg had similar LDL-C lowering effects to atorvastatin 80 mg 3

Real-world data shows that high-intensity rosuvastatin and atorvastatin have comparable cardiovascular outcomes in ACS patients, with no significant differences in the composite outcome of cardiovascular death, non-fatal ACS, and non-fatal stroke at 12 months 4.

Timing of Initiation

  • Statin therapy should be initiated as early as possible during hospitalization for ACS 1
  • LDL-C levels should be assessed during hospitalization 1
  • Lipid levels remain relatively stable in the first 4 days after ACS, allowing for accurate assessment and appropriate statin selection 5

Additional Considerations

Combination Therapy

If LDL-C goals are not achieved after 4-6 weeks with maximum tolerated rosuvastatin dose:

  1. Add ezetimibe 1, 2
  2. If goals still not achieved, consider adding a PCSK9 inhibitor 2

Safety Profile

  • Rosuvastatin 20-40 mg is generally well-tolerated in ACS patients 3, 6
  • Monitor for myalgia and other adverse effects 6
  • Assess liver function and creatine kinase at baseline and as clinically indicated 7

Common Pitfalls to Avoid

  1. Underdosing: Using moderate-intensity statins instead of high-intensity statins post-ACS fails to provide optimal cardiovascular protection 8
  2. Delayed initiation: Starting statin therapy late or after discharge may reduce benefits 1
  3. Inadequate monitoring: Failure to check lipid levels 4-12 weeks after initiating therapy to assess response 7
  4. Not adjusting therapy: Failing to add ezetimibe or PCSK9 inhibitors when LDL-C goals are not achieved with statin monotherapy 1, 2
  5. Discontinuation: Premature discontinuation of statin therapy significantly increases cardiovascular risk 8

In conclusion, rosuvastatin 20-40 mg daily is the recommended dose for patients post-ACS, with the goal of reducing LDL-C by at least 50% from baseline and achieving an LDL-C level <1.4 mmol/L (<55 mg/dL).

Related Questions

In a statin‑naïve patient with established atherosclerotic cardiovascular disease, should immediate high‑intensity therapy with atorvastatin 80 mg once daily or rosuvastatin 40 mg once daily be used, or is it preferable to start with atorvastatin 40 mg once daily or rosuvastatin 20 mg once daily?
When and how should a high dose of rosuvastatin (Crestor) be initiated, monitored, and what are the contraindications?
What is the recommended duration of atorvastatin 40 mg once daily therapy after an acute coronary syndrome?
Will switching a patient from Lipitor (atorvastatin) 40mg to Crestor (rosuvastatin) 20mg improve low-density lipoprotein (LDL) reduction?
Can rosuvastatin be used instead of atorvastatin for high‑intensity lipid‑lowering in an adult with atherosclerotic disease or a recent ischemic stroke/TIA?
What are the etiologies and treatment approaches for severe axonal sensory motor polyneuropathy with increased F (Fasciculation) waves?
At what triglyceride (TG) level should Ezetimibe be considered?
What is the recommended 1st line treatment for young patients with Chronic Myeloid Leukemia (CML) using 2nd generation Tyrosine Kinase Inhibitors (TKI)?
How often should labs be checked for a male on testosterone (hormone replacement therapy) for hypogonadism (low testosterone levels)?
What are the considerations for switching between dasatinib (Sprycel) and nilotinib (Tasigna) in cases of treatment failure or discontinuation?
What is the treatment for mild possible periorbital (around the eye) cellulitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.